News
- Lenalidomide for multiple myeloma
- Published on Mar 25, 2010
Phase 3 trials presented at the 51st Annual Meeting of the American Hematology Society in New Orleans show that lenalidomide (Revlimid) improves outcomes at all stages of multiple myeloma (MM).
- Oral MS treatments breakthrough
- Published on Mar 25, 2010
Three large randomised trials have provided strong evidence that new oral treatments for relapsing-remitting multiple sclerosis (MS) offer an advance on interferon beta-1a, with the prospect of transforming treatment if long-term studies provide evidence of safety (NEJM 2010; 362:387–401; 402–15; 416–26).
- Roflumilast: a novel approach to the management of COPD
- Published on May 28, 2009
Nycomed have submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for roflumilast (Daxas) as a once-daily oral treatment for patients with COPD associated with chronic bronchitis.
- CYT006-AngQb fails to reduce blood pressure in phase IIa study
- Published on May 12, 2009
A double-blind, placebo-controlled, phase IIa study has failed to demonstrate that Cytos Biotechnology’s hypertension vaccine, CYT006-AngQb, is effective in reducing blood pressure. An earlier phase IIa trial with the candidate vaccine had demonstrated clinically relevant and statistically significant blood pressure reductions, and as such the company are examining the new data in detail to try to explain and understand the negative result.
- New data for lipid modifying drug
- Published on May 12, 2009
A recent phase III study has found that patients with primary hypercholesterolaemia or mixed dyslipidaemia experienced reduced LDL-C of almost 48%, increased HDL-C of almost 28% and reduced triglyceride (TG) levels of about 33% after 12 weeks treatment with a combination of Tredaptive 2g (nicotinic acid/ laropiprant) and simvastatin (pooled across 20mg or 40mg).